Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Renalytix plc (RNLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/28/2023 8-K Quarterly results
08/21/2023 8-K Regulation FD Disclosure  Interactive Data
07/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Renalytix plc Issue of Shares LONDON and SALT LAKE CITY – July 17, 2023 - Renalytix plc , announces the repayment of $1.06 million of the Company’s convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 526,211 American Depositary Shares . After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $15.90 million. 1,052,422 new ordinary shares of £0.0025 each in the capital of the Company will be issued to settle the conversion of 526,211 ADSs, with each ADS representing two Ordinary Shares. An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 1,052,422 new ..."
07/03/2023 8-K Appointed a new director
Docs: "Renalytix plc Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY – July 3, 2023 - Renalytix plc , the first company to commercialize an FDA approved artificial intelligence enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company’s Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s life sciences industry executive leaders. She spent 32 years in bo..."
07/03/2023 8-K Regulation FD Disclosure  Interactive Data

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy